Related Experiment Video
Updated: Jun 2, 2026
08:14
Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
Published on: September 25, 2012
The prostate stem cell antigen represents a novel glioma-associated antigen
K D Geiger1, S Hendruschk, E P Rieber
1Department of Neuropathology, Institute for Pathology, Medical Faculty Carl Gustav Carus, D-01307 Dresden, Germany.
Oncology Reports
|April 20, 2011
Summary
Prostate stem cell antigen (PSCA) is notably absent in normal brain tissue but shows increased expression in high-grade gliomas (WHO grades III-IV). This finding suggests PSCA could be a valuable target for novel glioma immunotherapy strategies.
Area of Science:
- Neuro-oncology
- Cancer immunology
- Molecular pathology
Background:
- Malignant gliomas, particularly glioblastoma multiforme (GBM), are aggressive brain tumors often resistant to standard treatments.
- Immunotherapy offers a promising avenue for treating malignant gliomas, but requires identification of suitable tumor-associated antigens.
- Prostate stem cell antigen (PSCA) is a cell surface protein with potential as a therapeutic target.
Purpose of the Study:
- To investigate the expression patterns of Prostate Stem Cell Antigen (PSCA) in gliomas across different World Health Organization (WHO) grades.
- To evaluate the potential of PSCA as a diagnostic marker and a therapeutic target for glioma immunotherapy.
Main Methods:
- Quantitative RT-PCR, Western blotting, and immunohistochemistry were employed to analyze PSCA expression.
- A cohort of 210 human glial tumors (including oligodendrogliomas, ependymomas, and astrocytomas, with a significant number of glioblastomas) and control tissues were studied.
Main Results:
- PSCA was consistently absent in normal brain tissue.
- PSCA expression was significantly elevated in high-grade gliomas (WHO grades III-IV) compared to lower-grade tumors (WHO grades I-II) (p<0.001).
- Weak PSCA protein expression was observed in a subset of WHO grade I and II tumors.
Conclusions:
- Increased PSCA expression is strongly associated with advanced WHO grade III and IV gliomas.
- PSCA represents a potential diagnostic biomarker and a promising target for developing novel immunotherapeutic strategies against malignant gliomas.
